Nicht dopaminerge Antipsychotika: Hintergründe und neue Substanzen
- 26 April 2021
- journal article
- Published by Springer Science and Business Media LLC in InFo Neurologie + Psychiatrie
- Vol. 23 (4), 42-49
- https://doi.org/10.1007/s15005-021-1901-0
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- AntipsychotikaPublished by Springer Science and Business Media LLC ,2017
- Pathway-Specific Dopamine Abnormalities in SchizophreniaBiological Psychiatry, 2016
- Psychosis in Parkinson’s disease: identification, prevention and treatmentJournal of Neural Transmission, 2015
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trialThe Lancet, 2014
- Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/daySchizophrenia Research, 2012
- A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weightMolecular Psychiatry, 2012
- Towards a muscarinic hypothesis of schizophreniaMolecular Psychiatry, 2006
- NK3 receptor antagonists: the next generation of antipsychotics?Nature Reviews Drug Discovery, 2005
- The Role of Serotonin in Antipsychotic Drug ActionNeuropsychopharmacology, 1999
- Evidence of a Monoaminergic‐Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body DementiaJournal of Neurochemistry, 1990